COVID 19. Corona virus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: After routine treatment, the main group will be received the drug of the study. Drugs are in the sacher form. Every sacher contain 2 gram of Phyllanthus Emblica pow
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Lung involvement confirmed with chest imaging Hospitalized with: Fever (axillar or oral temperature = 38.0°) or Respiratory rate >24/min Or Cough Less than 8 days since illness onset Willingness of study participant to accept randomization to any assigned treatment arm Acceptance of non-participation in another study before the 28th day of the study
Exclusion criteria
Exclusion criteria: Physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. Severe liver disease Known allergic reaction to Phyllanthus Emblica Severe renal impairment Pregnant or breastfeeding women Transfer to another non-study hospital within the next 72 hours Receipt of any experimental treatment for COVID 19 within the 30 days prior to the time of the screening evaluation Angiotensin converting enzyme (ACE) inhibitor user
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral diagnostic test. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Polymerase chain reaction. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Daily. Method of measurement: Thermometer.;Chill. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Lymphocyte blood count. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Cell counter.;C_reactive protein. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Agglutination kit.;Chest CT scan. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: CT scan set. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehran Varnaseri Ghandali
Ahvaz University of Medical Sciences
Outcome results
None listed